

# POZEN<sup>®</sup>

INC.

The Pharmaceutical Development Company

## Corporate Headquarters:

1414 Raleigh Road, Suite 400  
Chapel Hill, North Carolina 27517  
Main: 919-913-1030 / Fax: 919-913-1039

## Contact:

Stephanie Bonestell  
Investor Relations  
919-913-1074

POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. With fewer than 40 employees, POZEN is focused in the pain area of innovative drug development and in creating strategic, high-value partnerships with larger pharmaceutical companies for the commercialization of the company's drug candidates.



## POZEN Product Pipeline Status

Therapeutic Category	Partner	Status
<b>Migraine</b> <i>Treximet®</i>	 Classen/Kline US Only	Marketed
<b>MT 400</b> (low dose)	To Be Determined WW (Except US)	Phase 3
<b>Chronic Pain</b> PN 40020 OA 65020	 AstraZeneca WW (Except Japan) To Be Determined	NDA – Filed Phase 1 – POC
<b>Cardiovascular</b> PA 32540 PA 08140 PA 10040	To Be Determined	Finalized SPA / Phase 3 Q3-2009 Phase 1 – POC Exploratory
<b>Oncology</b> CA 32540 CA 32520 CA 50040	To Be Determined	Exploratory Exploratory Exploratory
<b>Gastroenterology</b> ORD 2020	To Be Determined	Phase 1 – POC

**Treximet®** was FDA approved on April 15, 2008 for the acute treatment of migraine headaches. Utilizing POZEN's MT 400™ technology, *Treximet* is a novel combination of sumatriptan, formulated with GlaxoSmithKline's (GSK) RT Technology™, and naproxen sodium, in a single tablet. GSK is commercializing *Treximet*.

**PN 400** is being developed for the relief of the signs and symptoms associated with conditions such as osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk for developing NSAID-associated gastric ulcers. In August 2006, the company signed an exclusive global collaboration agreement with AstraZeneca for the co-development and commercialization of proprietary fixed dose combinations that provide the coordinated delivery of the NSAID, naproxen, with the proton pump inhibitor (PPI), esomeprazole magnesium, in a single tablet. PN 400 is designed to ensure adherence since the PPI is administered with every dose of NSAID. The New Drug Application (NDA) was submitted in June 2009.

**The PA/CA product candidates** are being developed as a "safer aspirin" and combine aspirin with a PPI for cardiovascular protection along with the potential reduction in the risk of colorectal cancer and adenomas. Adenomas are precursors of most colorectal cancers and prevention of adenomas may also prevent colorectal cancer, as reported in a March 2003 New England Journal of Medicine article. The PA/CA product candidates are intended to provide fewer gastrointestinal side effects and complications compared to an NSAID or enteric coated aspirin taken alone. POZEN conducted proof-of-concept studies with its PA product candidates. POZEN has a special protocol assessment for its Phase 3 pivotal trials for PA32540 and plans to begin these studies in mid-2009.

## Common Stock Listing:

Ticker Symbol: POZN  
NASDAQ Stock Market

**Founded:** 1996    **IPO:** October 2000

**Employees:** 32

**Website:** [www.pozen.com](http://www.pozen.com)

## Key Employees:

John R. Plachetka, Pharm.D.  
*Chairman, President & CEO*  
Elizabeth A. Cermak  
*EVP, Chief Commercial Officer*  
John G. Fort, M.D.  
*Chief Medical Officer*  
William L. Hodges, CPA  
*Sr. VP & Chief Financial Officer*  
Eric Orleans, Ph.D.  
*Sr. VP, Clinical Research*  
Gilda M. Thomas  
*Sr. VP & General Counsel*

## Analyst Coverage:

BMO Capital Markets,  
*Robert Hazlett*  
Brean Murray Carret & Co.  
*Jonathan Aschoff, Ph.D.*  
Citigroup Investment Research,  
*Lucy Lu*  
Cowen & Co.,  
*Ian Sanderson*  
Jefferies & Company, Inc.,  
*Eun Yang, Ph.D.*  
Wachovia Securities Equity Res.,  
*Michael Tong*  
Zacks Equity Research,  
*Jason Napodano*

## Upcoming Events:

### November 12-13<sup>th</sup>

The Credit Suisse Phoenix Healthcare Conference

## Recent News:

### October 30<sup>th</sup>

POZEN to Present at the Credit Suisse Healthcare Conference

### October 28<sup>th</sup>

POZEN Reports Third Quarter 2009 Results

For further information, see  
[www.pozen.com](http://www.pozen.com)